Document #		CRR			MR				IRB		
RADAR IRB STUDY				DRUG: Imatinib Mesylate			:				
	Data Source										
☐ IRB SAE Form ☐ Medwatch Form sent to IRB ☐ NCI SAE form sent to IRB ☐ Sponsor Form			☐ Cancer Center Clinical Trial Database (NOTIS)		☐ Clinical Trial Case Report For Local Mirror of report sent to cooperative group				Medical Record ☐ Patient Chart ☐ Imaging study report ☐ Pathology report ☐ Clinical chemistry		
		1	Protocol						, , , , , , , , , , , , , , , , , , ,		
Protocol name			Protoco			ol number			Sponsor		
			Report Date			ntes:					
To PI	To PI To IRB			To Spon			To FDA		SAE Report Numbers		
YYYY-MM-DD YYY		YY-MM-DD YYYY-MN		M-DD	D YYYY-MM-DD)				
				Demog	graphic						
Sex M		Age (years)			Weight (kg)			Height (cm)			
			Disea								
Tumor Type		Stage		□ Ye	Recurrence ☐ Yes ☐ No			Tumor Burden			
			4 4 1 4 /	Drug Adn				I	n.		
Drug Imatinib Meylate		51	tart date /	Restart	Sto	p Date			Doses		
iniatinio Megiate											
Other Chemotherapy											
Prednisone											
Methylprednisolone											
Other glucocorticosteroid											
Furosemide											
Torsemide											
Other Diuretic											
Other drugs											

Event date:		YYYY	M M		DD		
Eve	nt time:						
			H	н мм			
	Hoost Foilus	□ VEC					
Heart Failure	Heart Failure Signs / symptoms:	☐ YES ☐ Tachycardia > 90 ☐ Bradycardia < 50 ☐ Heart Palpitations ☐ Chest Pain ☐ Pericardia ☐ Pulmonary ☐ Legs ☐ Ankles ☐ Other		in >2 days / in 1 day ffusion	□ Dyspnea (SOB) sion □ Clubbing of fingers □ Other		
	Imaging studies:	☐ Chest Radiograph	□ EKG □ I	Echocardiogram	☐ Othe	r	
	Fracture	YES If yes, specify:		□ NO			
Fracture	Signs / symptoms:	☐ Bone Pain ☐ Swelling ☐ Loss of height	Other	□ Other			
	Imaging studies:	☐ X-ray	☐ Dexa scan t-score	☐ Bone scan		□ Other	
Infections	Infections	☐ YES If yes, specify site and organism:		□ NO			
Infe	Signs / symptoms:	\square ANC > 2.0 x 10 ⁹ \square For ANC < 1.0 x 10 ⁹		☐ Shock, severe acidosis (pH < 7.0), organ failure ☐ Other			
	Labs	☐ Blood Work ☐ Blood Cultures _	Other Cultures:	Other			
	Treatment	☐ IV antibiotic, antiviral of ☐ Operation or IV radiological	•				

Other events:							
Causality							
(Naranjo 2) Did the adverse event appear after	YES □	NO 🗖	UNKNOWN □				
(Naranjo 3) Did the symptoms or signs of the eagent to treat the event?	tion of an	YES 🗖	NO 🗖	UNKNOWN □			
(Naranjo 4) Did additional events occur with re		YES □	NO 🗖	UNKNOWN □			
Were alternative events mentioned in please specify:	e P.I? If so,	YES 🗖	NO 🗖	UNKNOWN □			
(Naranjo 5)Are there alternative causes (other than gefitinib) that could have on their own caused the event?							
(Naranjo 9) Did the patient have the event with similar drugs?	n previous administration of ge	efitinib or	YES 🗖	NO 🗖	UNKNOWN □		
Changes to protocol based at least in part on the	$\begin{array}{ccc} & & \textbf{Action} \\ \text{nis event} & & \text{YES} & \square \end{array}$	l		NO 🗖			
Changes to consent form based at least in part		NO 🗖					
Changes to consent form based at least in part on this event YES □ NO □							
Outcome:							
Imatinib Mesylate discontinued?	YES 🗖	NO 🗖					
Agent to treat signs and symptoms Heart Failure/Edema drug given?	YES If yes, specify Drug(s) Date(s) Dose Frequency						
Agent to treat signs and symptoms of a Fracture?	YES If yes, specify Drug(s) Date(s) Dose Frequency						
Agent to treat signs and symptoms of Infection?	YES If yes, specify Drug(s) Date(s) Dose Frequency						

PI Assessment:	☐ Probably Related	☐ Definitely Related	Comment:		
	☐ Possibly Related	☐ Unrelated ☐ N/A			
Data extraction:					
Start time:					
Stop time:					
Initials:					